Active Biotech : Company presentation May 2021

Active Biotech

May 2021

Disclaimer

• Certain statements made during the course of this presentation are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the company, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements.
• Statements made during the course of this presentation that are forward-looking are based on the company's current beliefs regarding a large number of factors affecting its business. There can be no assurance that (i) the company has correctly measured or identified all of the factors affecting its business or the extent of their likely impact, (ii) the available information with respect to these factors on which the Company's analysis is based is complete or accurate, (iii) the company's analysis is correct or (iv) the Company's strategy, which is based in part on this analysis, will be successful.
• All forward-looking statements speak only as of the date of this presentation or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by this cautionary statement. The company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this presentation.

2

Active Biotech in Brief

Detailed analysis has re-directed our efforts

• Ongoing projects focus on specialist indications within oncology and inflammation with high commercial potential
• One project in partnership and two fully owned
• Opportunity to leverage prior generated data to accelerate development
• Multiple clinical milestones during 2021

Experienced leadership & board with complementary skills

• Focused project-oriented organization
• Expanded board with topic expertise
• Broad international network of KOLs and experts

Finance & Corporate

• Listed on Nasdaq Stockholm (ticker: ACTI)
• • Market cap SEK 334M, USD 40M*
• Solid finances after successful rights issue in Jan 2021
• Strong shareholder base, incl MGA Holding, AP3 and AP4
• Funded in 1998 as spin-off from Pharmacia, based in Lund, Sweden

* As of April 29, 2021	3

A Growing Clinical Pipeline in Specialist Indications

4

Naptumomab: Tumor Directed Immunotherapy

	Mode of Action	• Tumor directed immunotherapy - selective T-cell redirection
	Indication	• Advanced or metastatic solid tumors
	Clinical status	• Phase Ib/II study in combination with checkpoint inhibitor
	durvalumab in patients with advanced solid tumors ongoing
	Safety	• Established safety & tolerability as monotherapy and in
	combination with standard cancer therapy
	Partnership	• Licensee agreement for global development and
	commercialization with NeoTX Ltd since 2016
	Market	• Substantial market opportunity within immuno-oncology
	• Global annualized sales of PD-(L)1 antibody therapies for
		advanced solid tumours exceeded $26bn in 2020
	IP and exclusivity	• Exclusivity by patent protection up to 2036
NAPTUMOMAB	5